Hyphens Pharma International - Phillip Securities 2024-08-21: New Products & Wider Distribution

• Hyphens Pharma International (SGX:1J5)'s 1H24 results were within expectations. Revenue and PATMI were 55%/46% of our forecast. PATMI surged 52% y-o-y to S$5.3mil in 1H24. Earnings growth was driven by restocking in specialty pharma as supply chains normalise, new products and expansion of the distribution network.
• - Read this at SGinvestors.io -
• Hyphens Pharma enjoys a dividend yield of 4% and Hyphens Pharma's share price trades at a P/E ratio of 7.7x FY24e. Our BUY recommendation and DCF-based Hyphens Pharma target price of S$0.35 is maintained.

The Positive

Specialty pharma recovery post disruption.

• - Read this at SGinvestors.io -

The Negative

Investment pain at DocMed.

• Read more at SGinvestors.io.

Above is an excerpt from a report by Phillip Securities Research.
Clients of Phillip Capital may be the first to access the full PDF report @ https://www.stocksbnb.com/.

Read also Phillip's most recent report:
2025-03-10 Hyphens Pharma International - Investing For Future Growth.

Price targets by 2 other brokers at Hyphens Pharma Target Prices.

Listing of research reports at Hyphens Pharma Analyst Reports.

Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividend Payout Dates & Corporate Actions,
Hyphens Pharma News